Oligosaccharides that block the adherence of bacteria to epithelial cells in vitro -lacto-N-neotetraose (LNnT) and its a2-3-and a2-6-sialylated derivatives -were tested for their abilities to attenuate the course of pneumococcal pneumonia and to prevent colonization of the nasopharynx in animal models. Intratracheal administration of these agents concurrently with bacteria dramatically decreased pneumococcal load in the lungs of rabbits and conferred protection from bacteremia. The oligosaccharides ameliorated pneumonia and bacteremia when given therapeutically 24 h after infection was established. When administered intranasally, neoglycoconjugates of the active oligosaccharides prevented colonization of the nasopharynx of infant rats. In addition to in vitro antiadherence properties, LNnT acted directly on cultured lung epithelial cell lines to induce changes such that pneumococcal adherence was prevented for prolonged periods. These activities encourage continued development of oligosaccharides as a class of potentially preventive and therapeutic agents for infectious diseases.
The initial event in bacterial infection of a mucosal surface Chang conjunctival cells or primary bronchial epithelial cells is attachment. Most commonly, this involves the specific recog- [7] . In the noninflamed lung, pneumococci bind to two ligands nition of a host cell surface glycoconjugate (herein termed on type II alveolar cells, the disaccharides GalNAc b1-4 Gal ligand) by a bacterial protein (herein termed adhesin). It has [8, 9] and GalNAc b1 -3 Gal [10] . In vitro, soluble versions of long been suggested that interference with attachment, particuthese carbohydrates block pneumococcal adherence to human larly by carbohydrates or homologs, could be an effective cells, and immobilized carbohydrates support pneumococcal means of interrupting the course of infection, and potentially, binding directly. A combination of the two oligosaccharides, as of transmission (reviewed in [1] ). For example, uropathogenic represented by asialo-ganglioside GM 2 and globoside, virtually Escherichia coli adhere to mannose determinants in the bladder eliminates bacterial adherence to type II lung cells in vitro or to digalactoside residues in the kidney. The instillation of [10] . This additive effect suggests that these glycoconjugates a-methyl mannoside into the bladder of animals infected with define independent receptors and that they explain a significant mannose-specific E. coli strongly reduces colonization [2] .
amount of adherence of pneumococci to the resting lung. Similarly, washing of the urinary tract with the Gal a1-4 Gal Progression to symptomatic pneumonia and bacteremia indisaccharide recognized by P fimbriae prevents upper urinary volves the initiation of the host acute-phase response. It has tract disease [3, 4] . Instillation of lactose into the respiratory been proposed that activation of host epithelial and endothelial tract reduced adherence of Bordetella pertussis to the airway cells by cytokines results in a shift in pneumococcal adherence in rabbits and improved bacterial clearance [5] . Aside from to new receptors, particularly the platelet-activating factor these few examples, the testing of carbohydrates as anti-infec-(PAF) receptor [11] . Coincident with the appearance of the tives in vivo has been limited because of lack of availability PAF receptor following inflammatory stimuli, pneumococci of most oligosaccharides at a reasonable cost.
undergo waves of enhanced adherence and invasion into euStreptococcus pneumoniae binds to human cells in the nasokaryotic cells [11] . The binding and invasion of activated cells pharynx, lung, middle ear, and bloodstream. These interactions is inhibited by PAF receptor antagonists and by oligosacchaare characterized by different ligand-adhesin pairings. In model rides containing N-acetyl glucosamine (a specificity with no systems of adherence to the upper respiratory tract, described activity in blocking adherence to resting cells). The activity of carbohydrate ligands include GlcNAc b1 -3 Gal as displayed the PAF receptor antagonists suggests that pneumococci may on buccal epithelial cells [6] 
Materials and Methods
way, NJ) is a competitive PAF receptor antagonist previously shown to block pneumococcal attachment to rabbit lung when Bacterial strains and culture conditions. For in vivo experiadministered intratracheally [11] and to block CD18-indepenments, the encapsulated S. pneumoniae strains AII of serotype 2 dent leukocyte recruitment to rabbit lung when administered and SIII of serotype 3 were grown in semisynthetic medium (C/Y) intravenously [14] . It was prepared as 2 mg/mL (5 mM) solution to mid-logarithmic phase, aliquoted 1:1 in 50% glycerol, and stored and further diluted in saline to achieve a dose of 10 mg/kg. at 070ЊC. For each experiment, one aliquot (100 mL) was resusAnti-CD18 monoclonal antibody IB4 (Merck) was administered pended in 10 mL of C/Y and grown to mid-logarithmic phase intravenously at 0.5 mg of purified protein/kg, a dose previously and further diluted in pyrogen-free saline.
determined to block CD18-dependent leukocyte migration into The unencapsulated strain R6 and the encapsulated AII, used the rabbit lung [14] . for in vitro adherence assays, were grown on trypticase soy agar ton, NY). With the exception of some a2-6-sialylated lacto-N-neotetraose
The course of disease was followed by quantitative culture of (6SLNnT; LSTc) from Oxford GlycoSystems (Rosedale, NY), all bronchoalveolar lavage (BAL) fluid. The animals were euthanized, carbohydrates were synthesized at Neose Technologies (Horsham, and BAL was performed with 2 1 10 mL saline supplemented PA). Oligosaccharides were at least 98% pure as estimated by with 5% heparin (Elkins-Sinn, Cherry Hill, NJ) and 0.1% methyl-HPLC. Contamination by endotoxin was õ1.25 EU/mg of carboene blue (Sigma). Lavage fluid volume was recorded, and the fluid hydrate (E-Toxate; Sigma). The purified products were characterwas plated on blood agar (100 mL neat, 1:10, and 1:100), and the ized by anthrone (total hexose) and resorcinol (sialic acid) reactions, proton nuclear magnetic resonance imaging (MRI), plates were incubated overnight at 37ЊC. The results are expressed Table 1 . Effect of oligosaccharides on bacterial load in lung when administered together with bacteria.
Structure Name Log cfu/mL of BAL
NOTE. Bacteria (1 -5 1 10 5 cfu) were incubated with 100 mM sugar prior to intratracheal instillation. Data are mean { SD log cfu/mL of bronchoalveolar lavage (BAL) fluid harvested 48 h after bacterial challenge. Values in parentheses are no. of rabbits per condition. LNnT Å lacto-N-neotetraose; LSTc Å a2-6-sialylated LNnT; Neu5Ac Å sialic acid; GalNAc Å N-acetylgalactosamine; GlcNAc Å N-acetylglucosamine. * Significant difference from control (P õ .01). the oligosaccharide LNnT and its a2-6-sialylated derivative,
MRI. Lungs from 13 healthy rabbits were scanned to establish LSTc, both of which decreased by Ç2 logs the bacterial load the baseline assessment for normal rabbit lung. Ten rabbits were in the lung at 48 h after challenge. Changes in structure of the challenged with pneumococci premixed with 100 mM LNnT (n Å 4), LSTc (n Å 2), or saline (n Å 4) intratracheally. Rabbits from oligosaccharide decreased efficacy to Ç1 log, as indicated by each group were euthanized at 24 (n Å 3) or 96 h (n Å 7). In substitution of a2-3-for a2-6-linked sialic acid (3SLNnT) addition, 3 rabbits were challenged with pneumococci, and LNnT at the nonreducing end or by the absence of the reducing termiwas administered 24 h later to 2 of them; the lungs were harvested nal lactosyl group (3SLn). identifying the location and size of pulmonary lesions as well Rat nasopharyngeal colonization model. Five-day-old infant as their relative fluid content by determining T1 and T2 relaxSprague-Dawley rats (n Å 5/group) were challenged according to an established protocol [16] . Bacteria and carbohydrate were mixed ation rates [15] . The effect of oligosaccharides on the extent for 15 min at room temperature, and then 10 6 bacteria were instilled and severity of pneumonia was evident on examination of the in 10 mL of saline into one nare. Three hours later, 50 mL of saline lung by MRI (figure 1). LNnT essentially eliminated the extenwas inoculated into one nare, and fluid extruded from the other nare was recovered. Number of viable bacteria was determined by counting colonies on blood agar plates. Statistical comparisons were made by use of Student's t test.
In vitro adherence of pneumococci. The human type II lung cell line A549 (American Type Culture Collection, Rockville, MD) was cultured in nutrient mixture F-12 Ham medium (Sigma) supplemented with 10% fetal calf serum (Sigma). At confluence, the cells were prepared for subculture with trypsin-0.05% EDTA (Sigma). For adherence assays, cells were transferred to Terasaki 60-well culture dishes (Robbins Scientific, Sunnyvale, CA) and cultured for another 24-48 h to form a confluent monolayer. Prior to the adherence assay, culture fluid was removed by washing the monolayers twice with medium F-12.
Adherence of pneumococci was assayed as previously described [9, 12] . Fluorescein-labeled strain R6 (5 1 10 7 /mL; identical adherence characteristics to those of the parent AII) were preincubated for 15 min at room temperature with carbohydrate and then added to the monolayer. For some assays, the carbohydrate was added to the monolayers before bacteria for varying amounts of time; then the monolayer was washed and challenged with untreated pneumococci. Adherence was assessed after 30 min at 37ЊC. Adherent pneumococci were counted visually with an inverted microscope (Diaphot-TDM; Nikon, Melville, NY) equipped for epifluorescence with an IF DM-510 filter and expressed as the number of attached bacteria per 100 lung cells. Values for 6-9 wells were Figure 1 . Effect of oligosaccharides on degree of lung injury in averaged, and each experiment was performed three to six times. pneumonia as measured by magnetic resonance imaging (MRI). Animals were challenged with pneumococci mixed with oligosaccharide (100 mM). The effects of LNnT and LSTc were magnified over time such that animals receiving LNnT cleared the infection by 96 h and those treated with LSTc had 1 log of bacteria/mL recoverable compared to ú3 logs of bacteria/mL in control animals (figure 2). Table 3 demonstrates that protection by LNnT and LSTc also extended to bacteremia at both 24 and 96 h after challenge. Only 1 of the 10 oligosaccharide-treated animals developed bacteremia at 24 h, and 3 of 10 at 96 h, compared with 4 of 5 control animals at both 24 and 96 h. In for LNnT-and LSTc-treated animals, respectively (n § 4/ group). Mean values for bacteremia were 670, 410, and 27 cfu/ mL for saline-, LNnT-, and LSTc-treated animals, respectively. whereas the GalNAc b1 -4 Gal isomer was inactive. A combiThe effect of the oligosaccharides was tested further by varynation of LNnT and GalNAc b1 -3 Gal did not further enhance ing the animal species, site of inoculation, serotype of the pneumococcal clearance. Three other structurally related neopneumococci, and the valency of the oligosaccharides (figure glycoproteins were ineffective. 3). By use of the infant rat model of nasopharyngeal carriage,
Oligosaccharides ameliorate the course of established pneuLNnT and LSTc presented in a multivalent form conjugated monia. In view of the ability of LNnT and LSTc to ameliorate to albumin reduced the number of highly virulent type 3 pneupneumococcal pneumonia when administered concurrently mococci recovered 3 h after challenge. GalNAc b1-3 Gal with the bacterial challenge, the ability of oligosaccharides to conjugate also was effective, consistent with the ability of this interrupt the course of established pneumonia was tested (table carbohydrate to decrease adherence to resting cells in vitro, 1; figure 4). Administration of LNnT (0.2 mL) 6 h after pneumococcal challenge decreased the bacterial load at 48 h in lung fluid and in blood by Ç1.5 log/mL. This effect persisted at 96 NOTE. n Å 5/group. Rabbits were challenged with bacteria-carbohydrate mixture (10 5 bacteria). Bacteremic Å ú10 cfu/mL of blood. LNnT, lacto-N-NOTE. Data are T2 relaxation time (ms); individual values are shown. For uninfected controls (n Å 13), mean { SD Å 20.5 { 3.8. LNnT, lacto-Nneotetraose; LSTc, a2-6-sialylated LNnT. * Significantly different from control (P õ .01). neotetraose; LSTc, a2-6-sialylated LNnT.
/ 9d31$$se41
07-16-97 13:24:13 jinfa UC: J Infect infiltrates into air spaces. Only minimal, varying degrees of interstitial thickening with heterophils were detected, with some hypertrophy and hyperplasia of alveolar-lining pneumocytes. The contribution of various structural components and derivatives of LNnT to bioactivity was examined. First, LNnT and the internal constituent LacNAc were tested for their ability to ameliorate the course of established pneumococcal pneumonia. Rabbits were challenged with 1 1 10 5 cfu and 6 h later received 20 nmol of LNnT or LacNAc (100 mM). Saline-treated animals (n Å 21) harbored 4.0 { 0.3 log cfu/mL of BAL fluid at 48 h. This was reduced by 1.7 logs on treatment with LNnT (n Å 8). There was no reduction in colony-forming units in animals receiving LacNAc (n Å 4).
Next, the efficacy of pentasaccharides generated by the addition of Neu5Ac a2-3 (3SLNnT), Neu5Ac a2 -6 (LSTc), or GalNAc b1 -3 to the nonreducing terminal Gal of LNnT was compared to that of LNnT (table 4) . Animals were treated 24 h after infection with 20 nmol of oligosaccharides, and BAL fluid was analyzed at 48 h. LNnT reduced the number of bacteria recovered in BAL fluids at 48 h by 1.1 log; 3SLNnT was more potent (1.4 log reduction), whereas LSTc and GalNAc and 3SLn were less effective.
Mechanisms of action of the oligosaccharides.
The oligosaccharides chosen for this study were forms of the five reported ligands for pneumococci on human cells as described h. Delaying LNnT therapy to 24 h decreased the efficacy in lung, but reduction in bacteremia reached the same end point in the literature. As expected, these carbohydrates blocked bacterial attachment to target A549 lung cells in vitro. LNnT, as seen after therapy begun at 6 h, that is, õ1 log of bacteria/ mL of blood at 96 h. The protective effect was also evident GalNAc b1 -3 Lac, and LSTc were the most effective competitive inhibitors of adherence, while 6SL was again inactive by MRI and quantitation of the amount of lung edema (table  2) . The protective effect of LNnT was apparent at a threshold (table 5) . These in vitro results are compatible with the hypothesis that the oligosaccharides function, at least in part, by between 10 and 50 mM. No increased efficacy was observed between 50 and 1000 mM. Further, the conjugation of LNnT blocking attachment of pneumococci to the lung. To test whether oligosaccharides can exert a preventive to albumin did not augment the molar potency of the oligosaccharide (data not shown).
effect when administered into the airway prior to infectious challenge, a group of animals was treated with 20 nmol of On histopathologic examination of the challenged lungs, a marked decrease in inflammatory infiltrates was observed in carbohydrate and 24 h later, after the concentration of LNnT would be expected to be substantially reduced, the animals animals treated with LNnT and LSTc relative to the salinetreated controls (figure 5). Macroscopic examination of the were challenged with pneumococci (table 6) . Quantitative culture of BAL fluid revealed that LNnT-and LSTc-treated control lungs showed congestion, hemorrhage, and firm consolidation of the affected pulmonary lobes. Microscopically, these animals harbored 2 -3 logs/mL fewer bacteria at 48 h and 1 -2 logs/mL fewer bacteria at 72 h than did saline control lungs had severe necrotizing, suppurative bronchopneumonia characterized by marked exudation of inflammatory infiltrates, animals. Bacteremia was present in only 1 of 3 animals in each of the treated groups versus 2 of 2 in the control group. including hemorrhage, fibrin accumulation, and heterophilic infiltration. In addition, there was prominent alveolitis as evi-
The sustained efficacy of the oligosaccharide (i.e., in the face of potential clearance of the competitive inhibitor) raised the denced by type II pneumocyte hypertrophy and hyperplasia. In contrast, the lungs from LNnT-and LSTc-treated animals possibility of a contribution of a noncompetitive mechanism of action to overall bioactivity. were pink and spongy (air-filled) and had mild, inflammatory / 9d31$$se41 07-16-97 13:24:13 jinfa UC: J Infect Several alternative mechanisms of action were sought. There saline vs. 7.4 { 0.2 1 10 6 after LNnT). Furthermore, LNnT maintained its protective effect in the near absence of leukowas no detectable change in the growth rate of pneumococci in the presence of LNnT (data not shown). The activity of the cytes. Inhibition of leukocyte recruitment by ú80% was achieved as described previously by use of a combination of oligosaccharides did not appear to involve an effect on leukocyte recruitment. The number of leukocytes in the BAL fluid intravenous anti-CD18 antibody and PAF receptor antagonist / 9d31$$se41 07-16-97 13:24:13 jinfa UC: J Infect . interactions of two highly virulent serotypes of pneumococci The possibility that LNnT might exert a direct effect on lung with lung and nasopharynx in vivo. The protective effect is cells, making them refractory to pneumococcal adherence, was also manifested by a decrease in the incidence of bacteremia examined in vitro (table 7) . Cultured A549 cells treated with resulting from intrapulmonary challenge. These biologic effects LNnT for between 5 and 30 min, and then washed repeatedly, are compatible with the established paradigm that ligand homodemonstrated a 40% -50% reduced capacity to support subselogs can alter the course of disease when presented at the quent pneumococcal adherence. This effect was sustained when time of bacterial challenge, that is, as preventive agents. Other the interval between removal of LNnT and addition of bacteria examples of this activity are the ability of oligosaccharides to was lengthened for up to 4 h but was lost by 24 h. Thus, a inhibit adherence of B. pertussis to rabbit ciliated pulmonary transient exposure to LNnT appeared to temporarily diminish epithelium [5] and to prevent adherence of E. coli to the urinary the lung cells' capacity to bind bacteria. tract [2, 4] . A novel and unexpectedly potent effect of LNnT and LSTc was detected on use of the oligosaccharides to treat established [10] ) and oropharyngeal cells [6] , was the most highly active inhibition. Data are means { SDs of 6 wells/experiment drawn from representaagent in several model systems used in this study. LacNAc, tive experiment repeated 3 times; values are no. of bacteria/100 A549 cells 6SLn, and 3SL or 6SL were inactive in vivo and in vitro.
(% of control). LNnT, lacto-N-neotetraose; LSTc, a2-6-sialylated LNnT.
* Significantly different from control (P õ .01).
3SLNnT, a molecule that combines the pneumococcal ligand / 9d31$$se41 07-16-97 13:24:13 jinfa UC: J Infect NOTE. LNnT, lacto-N-neotetraose; LSTc, a2-6-sialylated LNnT. * Carbohydrate administered at 0 h (20 nmol) followed by 10 5 bacteria at 24 h and harvesting of lung lavage fluid at 48 h.
† Carbohydrate administered at 0 h (20 nmol) followed by 5 1 10 7 bacteria at 24 h and harvesting of lavage fluid and blood at 72 h.
‡ Significantly different from control (P õ .01).
Neu5Ac a2,3 [7] and LNnT, resulted in a compound at least adherence. Alternatively, oligosaccharides may persist at high concentrations in the thin moisture film at the epithelial-air as potent as LNnT.
The partial correlation between bioactivity in vivo and inhiinterface and thereby block bacterial adherence even many hours after administration. LNnT did not increase the number bition of adherence in vitro suggests that the oligosaccharides reduce pneumococcal disease, at least in part, by interference of leukocytes recruited to the lung, and bacterial clearance was enhanced, even in animals in which leukocyte recruitment to with bacterial attachment to host cells. In this role, the oligosaccharides presumably act as soluble ligand homologs and bind the lung was inhibited. In vitro modeling of the protective effect suggested it may arise at the level of the pulmonary to the bacteria, preventing their subsequent attachment to host cells. It is also possible, however, that the oligosaccharides epithelium: Lung cells treated with LNnT in vitro supported less pneumococcal adherence for many hours after removal of have additional activities that promote clearance of pneumococci. This is most directly suggested by the ability of the the oligosaccharide from the culture medium. We conclude that LNnT most probably ameliorates pneumooligosaccharides to decrease the amount of pneumococci recovered in BAL fluid even when administered 24 h before the coccal infection in two ways. When the oligosaccharide is present in the lung, it can act as a direct competitive inhibitor of bacteria. In this setting, it seems likely that the oligosaccharide would be diluted and/or cleared, resulting in a local concentrapneumococcal adherence to lung cells. However, the exposure of pulmonary epithelial cells to LNnT may also render the cells tion too low to permit activity as a competitive inhibitor of relatively refractory to subsequent pneumococcal adherence. The mechanism of this latter effect is unknown. One possibility involves changes in cellular activation induced by the carbohy- Table 7 . LNnT pretreatment of lung cells protects against adherence in vitro.
drate. An example of this novel activity for a carbohydrate was found in the literature. Protein conjugates of LNnT and its a1- recognized by pneumococci as determined from literature.
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